Subtype
Breast Carcinoma
CI-CAN-00000594Explore in graph →
873 active trials12 approved drugs113 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000594Explore in graph →
Clinical trials
2,394 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (365)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03876886 | The Trial Comparing Dose-dense AC-T With TP as Adjuvant Therapy for TNBC With Homologous Recombination Repair Deficiency | unknown | Phase 3 | 200 | Chinese Academy of Medical SciencesOTHER | 1 | Mar 21, 2019 | clinicaltrials |
| NCT03881878 | TAHP for Patients With HER2-positive Early Breast Cancer and Subsequent AHP Adjuvant tHerapy After Surgery | unknown | Phase 1 / Phase 2 | 67 | Samsung Medical CenterOTHER | 1 | Mar 21, 2019 | clinicaltrials |
| NCT00886535 | Effect of Pharmacogenomics Differences in Phase I and II Metabolism of Tamoxifen on Efficacy and Toxicity | completed | — | 41 | Milton S. Hershey Medical CenterOTHER | 1 | Mar 14, 2019 | clinicaltrials |
| NCT00063934 | Oblimersen Plus Doxorubicin and Docetaxel in Treating Patients With Metastatic or Locally Advanced Breast Cancer | terminated | Phase 1 / Phase 2 | 31 | National Cancer Institute (NCI)NIH | 1 | Mar 5, 2019 | clinicaltrials |
| NCT03847818 | Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Chemotherapy in Patients With HER2 Positive Breast Cancer | unknown | N/A | 268 | Shandong UniversityOTHER | 0 | Mar 1, 2019 | clinicaltrials |
| NCT01881230 | Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)(tnAcity) | completed | Phase 2 / Phase 3 | 191 | CelgeneINDUSTRY | 12 | Feb 21, 2019 | clinicaltrials |
| NCT03430765 | Preventing Persistent Pain and Reducing Depressive and Anxious Symptoms Following Mastectomy and Lumpectomy | completed | N/A | 62 | Katherine HadlandsmythOTHER | 1 | Feb 11, 2019 | clinicaltrials |
| NCT02557776 | Written Genetic Counseling and Mutation Analysis of BRCA1 and BRCA2 to Patients With Breast Cancer(BRCAsearch) | completed | N/A | 542 | Lund UniversityOTHER | 1 | Feb 6, 2019 | clinicaltrials |
| NCT02580448 | CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448)(CLARITY-01) | completed | Phase 1 / Phase 2 | 175 | Innocrin PharmaceuticalINDUSTRY | 1 | Feb 1, 2019 | clinicaltrials |
| NCT02773784 | Comparison of CNB and Surgical Specimens for ER, PgR, HER2 Status and Ki67 Index in Invasive Breast Cancer. | completed | — | 314 | Peking UniversityOTHER | 1 | Jan 18, 2019 | clinicaltrials |
| NCT03799679 | Albumin-Bound Paclitaxel Followed by Epirubicin in Combination With Cyclophosphamide in Triple Negative Breast Cancer | unknown | Phase 4 | 60 | Fudan UniversityOTHER | 1 | Jan 10, 2019 | clinicaltrials |
| NCT02299635 | A Study Evaluating PF-03084014 In Patients With Advanced Breast Cancer With Or Without Notch Alterations | terminated | Phase 2 | 19 | PfizerINDUSTRY | 6 | Jan 8, 2019 | clinicaltrials |
| NCT02511301 | Circadian Thermal Sensing to Detect Breast Disease | unknown | Phase 1 / Phase 2 | 173 | Cyrcadia HealthINDUSTRY | 1 | Jan 3, 2019 | clinicaltrials |
| NCT02599194 | 18F-FSPG PET/CT for Cancer Patients on Therapy | completed | Phase 2 | 7 | Andrei IagaruOTHER | 1 | Jan 3, 2019 | clinicaltrials |
| NCT03238703 | Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer | withdrawn | Phase 4 | 0 | Fred Hutchinson Cancer CenterOTHER | 1 | Dec 27, 2018 | clinicaltrials |
| NCT01277757 | Akt Inhibitor MK2206 in Treating Patients With Advanced Breast Cancer | completed | Phase 2 | 30 | National Cancer Institute (NCI)NIH | 1 | Dec 19, 2018 | clinicaltrials |
| NCT03775928 | Compare Apatinib Plus Capecitabine Versus Capecitabine in Maintenance Therapy for Patients With Advanced Triple-negative Breast Cancer | unknown | Phase 2 | 80 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Dec 14, 2018 | clinicaltrials |
| NCT00425672 | ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment | completed | Phase 1 / Phase 2 | 15 | University of WashingtonOTHER | 1 | Dec 5, 2018 | clinicaltrials |
| NCT01912963 | Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer | terminated | Phase 2 | 32 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 5, 2018 | clinicaltrials |
| NCT00733408 | Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer | completed | Phase 2 | 59 | University of WashingtonOTHER | 1 | Dec 4, 2018 | clinicaltrials |
| NCT00869206 | Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement | completed | Phase 3 | 1,822 | Alliance for Clinical Trials in OncologyOTHER | 2 | Nov 7, 2018 | clinicaltrials |
| NCT03710018 | Impact of Tumor Bed Localisation on Dosimetry Boost Irradiation in Patients Undergoing Breast Conserving Surgery | unknown | — | 21 | Tata Memorial CentreOTHER | 1 | Oct 17, 2018 | clinicaltrials |
| NCT01632332 | Vaccine Therapy in Treating Patients With Previously Treated Stage II-III HER2-Positive Breast Cancer | completed | Phase 1 | 22 | Mayo ClinicOTHER | 1 | Oct 9, 2018 | clinicaltrials |
| NCT02521961 | Support Group Program in Improving Quality of Life in Underserved Urban Latina Breast Cancer Survivors | completed | N/A | 10 | Fred Hutchinson Cancer CenterOTHER | 1 | Oct 5, 2018 | clinicaltrials |
| NCT03358004 | the Role of Two Different Metronomic Chemotherapy Regimens in Locally Advanced or Metastatic Triple Negative Breast Cancer Patients (TNBC) as Maintenance Therapy After First Line Treatment(VICTOR3) | terminated | Phase 2 | 4 | Mario Negri Institute for Pharmacological ResearchOTHER | 3 | Oct 5, 2018 | clinicaltrials |
| NCT01986426 | LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or Pembrolizumab | completed | Phase 1 | 80 | Lytix Biopharma ASINDUSTRY | 5 | Oct 3, 2018 | clinicaltrials |
| NCT03692689 | Safety and Efficacy of SCT200 in Patients With Relapsed or Metastatic Triple Receptor Negative Breast Cancer | unknown | Phase 2 | 30 | Sinocelltech Ltd.INDUSTRY | 1 | Oct 2, 2018 | clinicaltrials |
| NCT03684863 | Capecitabine in HER-2 Positive Breast Cancer With Pathologic Residual Tumors After Preoperative Chemotherapy | unknown | Phase 2 | 200 | Shandong Cancer Hospital and InstituteOTHER | 0 | Sep 26, 2018 | clinicaltrials |
| NCT01638247 | Tamoxifen +/- GnRH Analogue vs Aromatase Inhibitor + GnRH Analogue in Male Breast Cancer Patients(MALE) | completed | Phase 3 | 56 | GBG Forschungs GmbHOTHER | 1 | Sep 19, 2018 | clinicaltrials |
| NCT01194440 | Zoledronic Acid in Aromatase Inhibitor Induced Musculoskeletal Symptoms | completed | Phase 2 | 63 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Sep 12, 2018 | clinicaltrials |
| NCT01493310 | Nab-paclitaxel (Abraxane) With or Without Mifepristone in Patients With Advanced Breast Cancer | completed | Phase 1 | 9 | University of ChicagoOTHER | 1 | Sep 12, 2018 | clinicaltrials |
| NCT02046421 | Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 1 | 31 | University of ChicagoOTHER | 1 | Sep 11, 2018 | clinicaltrials |
| NCT02650635 | TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors | terminated | Phase 1 | 4 | Mayo ClinicOTHER | 1 | Sep 5, 2018 | clinicaltrials |
| NCT02224807 | Effects of Diet and Exercise on Ductal Carcinoma in Situ(DCIS) | completed | N/A | 32 | University of Alabama at BirminghamOTHER | 1 | Aug 31, 2018 | clinicaltrials |
| NCT02225470 | Eribulin Versus Vinorelbine in Subjects With Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes | completed | Phase 3 | 530 | Eisai Co., Ltd.INDUSTRY | 1 | Aug 28, 2018 | clinicaltrials |
| NCT02364960 | Targeted Intraoperative Therapy Registry at Bethesda North Hospital (TARGIT)(TARGIT) | terminated | — | 16 | TriHealth Inc.OTHER | 1 | Aug 22, 2018 | clinicaltrials |
| NCT02150525 | Effect of Omega 3 on Atrophic Vaginitis in Breast Cancer Survivors | completed | Phase 2 | 52 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Aug 9, 2018 | clinicaltrials |
| NCT02898376 | Clinical Benefit of Spa Care on Severe Radiation-induced Fibrosis After Postoperative Radiotherapy for Breast Cancer(FIBROTHERME) | unknown | Phase 3 | 142 | Institut de Cancérologie de LorraineOTHER | 1 | Aug 8, 2018 | clinicaltrials |
| NCT03000764 | RNA and Heat Shock Protein Biomarkers in Radiation-induced Fibrosis in Breast Cancer(SPLICI-Rad) | completed | N/A | 20 | Institut de Cancérologie de LorraineOTHER | 1 | Aug 8, 2018 | clinicaltrials |
| NCT03408769 | Metastatic Breast Carcinoma and Women Sexual Quality of Life(SexoMBC) | completed | — | 30 | Institut de Cancérologie de LorraineOTHER | 1 | Aug 8, 2018 | clinicaltrials |
| NCT01394211 | Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer | terminated | Phase 2 | 2 | University of ArizonaOTHER | 1 | Jul 26, 2018 | clinicaltrials |
| NCT02095743 | Tolerance of PICC Line Versus Implanted Port for Adjuvant Chemotherapy in Early Breast Cancer(EPIC) | unknown | Phase 2 | 256 | Centre Henri BecquerelOTHER | 1 | Jul 24, 2018 | clinicaltrials |
| NCT00986609 | MUC1 Vaccine for Triple-negative Breast Cancer | completed | Early Phase 1 | 29 | Joseph Baar, MD, PhDOTHER | 1 | Jul 23, 2018 | clinicaltrials |
| NCT01344031 | MK2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole and Fulvestrant in Treating Postmenopausal Women With Metastatic Breast Cancer | completed | Phase 1 | 31 | National Cancer Institute (NCI)NIH | 1 | Jul 23, 2018 | clinicaltrials |
| NCT03326258 | Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Jul 18, 2018 | clinicaltrials |
| NCT02168179 | KeraStat Skin Therapy in Treating Radiation Dermatitis in Patients With Newly Diagnosed Stage 0-IIIA Breast Cancer | withdrawn | N/A | 0 | Wake Forest University Health SciencesOTHER | 1 | Jul 5, 2018 | clinicaltrials |
| NCT03045393 | Mirvetuximab Soravtansine (IMG853) in Folate Receptor Alpha-expressing TNBC(IMGN853) | withdrawn | Phase 1 | 0 | Duke UniversityOTHER | 1 | Jul 5, 2018 | clinicaltrials |
| NCT03576521 | Evaluation of Ocoxin®-Viusid® in Breast Cancer | completed | Phase 2 | 120 | Catalysis SLINDUSTRY | 1 | Jul 3, 2018 | clinicaltrials |
| NCT02023008 | Interactive Gentle Yoga in Improving Quality of Life in Patients With Stage I-III Breast Cancer Undergoing Radiation Therapy | terminated | N/A | 6 | Wake Forest University Health SciencesOTHER | 1 | Jul 2, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Mar 21, 2019source: clinicaltrials